NYC startupfromFortune1 week agoFrom drought to demand: Biotech IPOs roar back with Kailera and Alamar | FortuneInvestors are returning to biotech IPOs, as demonstrated by Alamar Biosciences and Kailera Therapeutics' successful public offerings.